Bioengineered factor IX molecules with increased catalytic activity improve the safety and efficacy of helper-dependent adenoviral vectors (HDAd) for hemophilia B gene therapy - Brunetti-Pierri, N; Grove, N; Zuo, Y (Mol Ther, 2008)
et al.